

**Mental Health Medication Advisory Committee
Meeting Agenda, Open Session
December 9, 2015, 2:00-4:00pm**

Meeting Location: HP Enterprise Services, Capital Room, 6511 SE Forbes Ave, Topeka, KS 66619

Committee Members: Susan Mosier, MD, MBA, FACS (Chair), Vishal Adma, MD, MS, CMQ, CPE, Holly Cobb, ARNP, Nicole Ellermeier, PharmD, Bradley Grinage, MD, Rebecca Klingler, MD, Charles Millhuff, DO, Karen Moeller, PharmD, BCPP, Taylor Porter, MD

KDHE Staff: Kelley Melton, PharmD, Liane Larson, PharmD, Aaron Dunkel, KDHE Deputy Secretary (appointed temporary chair)

MCO Staff: Jonalan Smith, PharmD, FASCP, Sosunmolu Shoyinka, MD, Jennifer Murff, RPh, John Esslinger, MD, MMM, Lisa Todd, RPh, BBA, William Mack, MD

I. Call to Order

- A. Introductions
- B. Announcements

II. Old Business

- A. Review and Approval of September 1, 2015 Meeting Minutes
- B. Review and Approval of October 28, 2015 Meeting Minutes
- C. Prior Authorization Criteria
 - 1. Antipsychotic Dosing Limits – Review proposed daily dose limits for patients prescribed antipsychotic drugs.
 - a. Prior Authorization Criteria
 - b. Clinical Public Comment *
 - c. Committee Discussion

III. New Business

- A. Prior Authorization Criteria
 - 1. Use of Multiple Concurrent SNRIs – Review proposed clinical criteria for patients prescribed multiple concurrent antidepressants.
 - a. Prior Authorization Criteria
 - b. Clinical Public Comment *
 - c. Committee Discussion

2. Use of Multiple Concurrent SSRIs – Review proposed clinical criteria for patients prescribed multiple concurrent antidepressants.

- a. Prior Authorization Criteria
- b. Clinical Public Comment *
- c. Committee Discussion

3. Use of Multiple Concurrent antidepressants – Review proposed clinical criteria for patients prescribed multiple concurrent antidepressants.

- a. Prior Authorization Criteria
- b. Clinical Public Comment *
- c. Committee Discussion

4. Use of Benzodiazepines and Buprenorphine Products – Review proposed clinical criteria for medication assisted treatment program patients prescribed benzodiazepines.

- a. Prior Authorization Criteria
- b. Clinical Public Comment *
- c. Committee Discussion

IV. Process Improvement Initiatives - For informational purposes only

A. Preferred Prescriber Status
1. Committee Discussion

B. Pre-Approval Process
1. Committee Discussion

V. Open Public Comment*

VI. Adjourn

* Clinical and open public comment requests and written testimony must be submitted 1 week prior to meeting to llarson@kdheks.gov. If providing clinical comment, please indicate which agenda item you are requesting to comment on. Time limits during period of comment will be determined based on number of requests received.

****THIS AGENDA IS SUBJECT TO CHANGE****